Please login to the form below

rosuvastatin calcium

This page shows the latest rosuvastatin calcium news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca settles with generic rivals in Crestor patent challenge

The company said it has entered into a settlement agreement with Actavis and Egis Pharmaceuticals over their plan to launch generic Crestor (rosuvastatin calcium), blocking competition for the product until May ... Actavis (formerly Watson Pharma) filed

Latest news

Crestor can't top Lipitor in head-to-head study

A study comparing the effects of AstraZeneca's Crestor (rosuvastatin calcium) with Pfizer's Lipitor (atorvastatin calcium) in has found no difference between the statin drugs in preventing the progression of ... The SATURN trial was designed to look at
AZ's Q3 income up as sales stay flat

The company said more than $350m of revenue was lost due to generic competition, cancelling out strong performances for statin Crestor (rosuvastatin calcium), antipsychotic Seroquel XR (quetiapine fumarate) and Symbicort
AstraZeneca partners with cooking website

AstraZeneca (AZ) has entered into a partnership with Food University, a web-based culinary platform, to help educate consumers about healthy eating in support of the company's medication Crestor (rosuvastatin ... calcium), which is approved to lower
AZ sees decrease in Q4 profit

Revenue for the year remained flat at around $33bn. Well-performing drugs for the company included cholesterol product, Crestor (rosuvastatin calcium), with the drug seeing a revenue increase of 26 per
Generics and legal costs affect AZ profits

The company reported double-digit sales growth for cholesterol drug Crestor (rosuvastatin calcium), for which AZ has filed a law suit against Watson Pharmaceuticals in an effort to block the company

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest appointments

Evan Lippman joins Aileron Therapeutics

Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development